Illumina (NASDAQ:ILMN) Stock Price Up 5.7%

Illumina, Inc. (NASDAQ:ILMNGet Rating) shares traded up 5.7% during mid-day trading on Wednesday . The company traded as high as $207.01 and last traded at $205.80. 36,952 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,461,272 shares. The stock had previously closed at $194.70.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Robert W. Baird reduced their price objective on shares of Illumina from $306.00 to $215.00 in a research report on Friday, August 12th. Canaccord Genuity Group reduced their price target on shares of Illumina from $450.00 to $380.00 and set a “buy” rating for the company in a research report on Friday, August 12th. Credit Suisse Group initiated coverage on shares of Illumina in a research report on Wednesday, August 24th. They issued a “neutral” rating and a $230.00 price target for the company. Cowen reduced their price target on shares of Illumina to $327.00 in a research report on Monday, August 15th. Finally, Barclays reduced their price target on shares of Illumina to $130.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $257.27.

Illumina Stock Performance

The company has a current ratio of 1.00, a quick ratio of 0.82 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $206.99 and a 200 day simple moving average of $247.75.

Illumina (NASDAQ:ILMNGet Rating) last announced its quarterly earnings data on Thursday, August 11th. The life sciences company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.63 by ($0.06). The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.22 billion. Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The company’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.87 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 2.83 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other news, SVP Alexander Aravanis sold 539 shares of the firm’s stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total value of $107,800.00. Following the sale, the senior vice president now owns 3,346 shares in the company, valued at $669,200. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Illumina

A number of institutional investors have recently bought and sold shares of ILMN. Private Trust Co. NA acquired a new stake in Illumina during the second quarter worth $25,000. Glassman Wealth Services boosted its stake in Illumina by 72.9% during the second quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock worth $27,000 after buying an additional 62 shares in the last quarter. Asset Dedication LLC lifted its holdings in shares of Illumina by 75.0% during the first quarter. Asset Dedication LLC now owns 77 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 33 shares during the period. Farmers & Merchants Investments Inc. bought a new position in shares of Illumina during the first quarter valued at $30,000. Finally, Tcwp LLC bought a new position in shares of Illumina during the first quarter valued at $31,000. Institutional investors and hedge funds own 86.12% of the company’s stock.

Illumina Company Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

See Also

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.